NFKB1 and inflammatory bowel disease: In autoimmune conditions such as autoimmune hepatitis, type 1 diabetes, rheumatoid arthritis, Sjögren’s disease, systemic lupus erythematosus, multiple sclerosis, and inflammatory bowel disease, Par2-mediated inflammation has been linked to the amplification of inflammatory cascades through pathways like NF-κB and MAPK.